Literature DB >> 8524877

Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4.

T Yoshimoto1, A Bendelac, J Hu-Li, W E Paul.   

Abstract

SJL mice produce little or no IgE in response to polyclonal stimulation with anti-IgD antibody and fail to express interleukin 4 (IL-4) mRNA in the spleen 5 days after injection of anti-IgD, in contrast to other mouse strains that produce substantial amounts of IgE and IL-4. Because IL-4 is critical in IgE production, the possibility that SJL mice are poor IgE producers because their naive T cells fail to differentiate into IL-4 producers must be seriously considered. IL-4 itself is the principal factor determining that naive T cells develop into IL-4 producers. A major source of IL-4 for such differentiation is a population of CD1-specific CD4+ T cells that express NK1.1. These cells produce IL-4 within 90 min of anti-CD3 injection. T cells from SJL mice fail to produce IL-4 in response to injection of anti-CD3. Similarly, SJL T cells and CD4+ thymocytes do not produce IL-4 in response to acute in vitro stimulation. SJL T cells show a marked deficiency in CD4+ cells that express the surface receptors associated with the NK1.1+ T-cell phenotype. This result indicates that the SJL defect in IgE and IL-4 production is associated with, and may be due to, the absence of the CD4+, NK1.1+ T-cell population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8524877      PMCID: PMC40517          DOI: 10.1073/pnas.92.25.11931

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Suppression of IgE antibody production in SJL mice. I. Nonspecific suppressor T cells.

Authors:  N Watanabe; S Kojima; Z Ovary
Journal:  J Exp Med       Date:  1976-04-01       Impact factor: 14.307

2.  Experimental allergic encephalomyelitis in inbred and outbred mice.

Authors:  S Levine; R Sowinski
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

3.  A subset of CD4+ thymocytes selected by MHC class I molecules.

Authors:  A Bendelac; N Killeen; D R Littman; R H Schwartz
Journal:  Science       Date:  1994-03-25       Impact factor: 47.728

Review 4.  Lymphocyte responses and cytokines.

Authors:  W E Paul; R A Seder
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  An avidin--biotin microELISA for rapid measurement of total and allergen-specific human IgE.

Authors:  P V Subba Rao; N L McCartney-Francis; D D Metcalfe
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

6.  A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma.

Authors:  R L Coffman; J Carty
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

7.  Genetic control of the natural killer cell activity in SJL and other strains of mice.

Authors:  S G Kaminsky; I Nakamura; G Cudkowicz
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  CD1 recognition by mouse NK1+ T lymphocytes.

Authors:  A Bendelac; O Lantz; M E Quimby; J W Yewdell; J R Bennink; R R Brutkiewicz
Journal:  Science       Date:  1995-05-12       Impact factor: 47.728

9.  An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans.

Authors:  O Lantz; A Bendelac
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

10.  Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease.

Authors:  M K Racke; A Bonomo; D E Scott; B Cannella; A Levine; C S Raine; E M Shevach; M Röcken
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more
  52 in total

1.  CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice.

Authors:  Y Ikehara; Y Yasunami; S Kodama; T Maki; M Nakano; T Nakayama; M Taniguchi; S Ikeda
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Induction of autoreactive CD8+ cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Robert S Fujinami
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE.

Authors:  Gregory D Gregory; Shveta S Raju; Susan Winandy; Melissa A Brown
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

4.  Do NKT cells control autoimmunity?

Authors:  Lucienne Chatenoud
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 5.  Regulation of immune responses by CD1d-restricted natural killer T cells.

Authors:  Luc Van Kaer
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Contribution of mast cells to the T helper 2 response induced by simultaneous subcutaneous and oral immunization.

Authors:  I Aoki; S Itoh; S Yokota; S Tanaka; N Ishii; K Okuda; M Minami; D M Klinman
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

7.  TCR Valpha14 natural killer T cells function as effector T cells in mice with collagen-induced arthritis.

Authors:  Y Ohnishi; A Tsutsumi; D Goto; S Itoh; I Matsumoto; M Taniguchi; T Sumida
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 8.  The role of invariant natural killer T cells in lupus and atherogenesis.

Authors:  Amy S Major; Ram R Singh; Sebastian Joyce; Luc Van Kaer
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 9.  Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells.

Authors:  Kazunori Onoé; Yoshiki Yanagawa; Keita Minami; Norifumi Iijima; Kazuya Iwabuchi
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 10.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.